{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:11:30Z","timestamp":1784913090471,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Intravenous ferric carboxymaltose (\n                      <jats:italic>FCM<\/jats:italic>\n                      ) is frequently used to treat iron deficiency in lung transplant recipients (\n                      <jats:italic>LTRs<\/jats:italic>\n                      ). Hypophosphatemia is a known adverse event after FCM administration, with reported significant hypophosphatemia following FCM administration in renal and heart transplant recipients. This study aimed to assess the incidence of hypophosphatemia after FCM administration and to identify potential risk factors in LTRs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, single-center study included LTRs treated with FCM during post-transplant follow-up between 2015 and 2022 at the University Hospital Zurich. Patients were included if serum phosphate was measured within six months before and after FCM infusion. Phosphate levels and clinical data were extracted from electronic records, and hypophosphatemia was classified by severity. Changes in phosphate levels over time were analyzed using mixed-effects models, and multivariable logistic regression was used to identify predictors of hypophosphatemia. Of note, phosphate measurements were obtained at routine follow-up visits, with the first post-infusion measurement occurring at a median of 32 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 110 LTRs receiving FCM, 54.5% (\n                      <jats:italic>n<\/jats:italic>\n                      = 60) developed hypophosphatemia (\u2264 0.81 mmol\/L). Mild, moderate, and severe hypophosphatemia occurred in 23.6% (\n                      <jats:italic>n<\/jats:italic>\n                      = 26), 24.5% (\n                      <jats:italic>n<\/jats:italic>\n                      = 27), and 6.4% (\n                      <jats:italic>n<\/jats:italic>\n                      = 7) of patients, respectively. Use of 1000 mg FCM was associated with a higher risk of hypophosphatemia compared to 500 mg (OR (95% CI) of 2.54 (1.15\u20135.59)), increasing further after adjusting for baseline phosphate (OR (95% CI) of 5.18 (1.90\u201314.14)). Among patients with new-onset hypophosphatemia, 76% recovered within a median of 56 days. No serious clinical adverse events directly attributable to hypophosphatemia were documented.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Hypophosphatemia frequently occurred after FCM infusion in LTRs, particularly following higher doses. Transplant physicians should be mindful of this risk and consider using individualized FCM doses or alternative intravenous iron formulations with lower hypophosphatemia risk, such as ferric derisomaltose\u00a0in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.ClinicalTrials.gov\" ext-link-type=\"uri\">www.ClinicalTrials.gov<\/jats:ext-link>\n                      , NCT 06112236\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11739-026-04470-3","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:57:01Z","timestamp":1784912221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypophosphatemia after intravenous ferric carboxymaltose in lung transplant recipients"],"prefix":"10.1007","clinical-trial-number":[{"clinical-trial-number":"nct06112236","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0780-8320","authenticated-orcid":false,"given":"Fabrizio","family":"Pumo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriane Andrina","family":"Sievi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gaisl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Steinack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse","family":"Marck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Hage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ulrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mac\u00e9","family":"Schuurmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Roeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"issue":"4","key":"4470_CR1","doi-asserted-by":"publisher","first-page":"A6457","DOI":"10.1016\/j.chest.2023.07.4163","volume":"164","author":"D Steck","year":"2023","unstructured":"Steck D, Mostofi N, Tillinghast K, Wu D, Scovotti J, Cheng D et al (2023) The incidence of hypophosphatemia after lung transplant surgery: preliminary data from two major centers. Chest 164(4):A6457","journal-title":"Chest"},{"key":"4470_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116202","volume":"154","author":"B Schaefer","year":"2022","unstructured":"Schaefer B, Tobiasch M, Wagner S, Glodny B, Tilg H, Wolf M et al (2022) Hypophosphatemia after intravenous iron therapy: comprehensive review of clinical findings and recommendations for management. Bone 154:116202","journal-title":"Bone"},{"issue":"1","key":"4470_CR3","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/TP.0000000000000823","volume":"100","author":"M Wolf","year":"2016","unstructured":"Wolf M, Weir MR, Kopyt N, Mannon RB, Von Visger J, Deng H et al (2016) A prospective cohort study of mineral metabolism after kidney transplantation. Transplant 100(1):184\u2013193","journal-title":"Transplant"},{"key":"4470_CR4","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nrneph.2015.153","volume":"11","author":"LC Baia","year":"2015","unstructured":"Baia LC, Heilberg IP, Navis G, de Borst MH (2015) Phosphate and FGF-23 homeostasis after kidney transplantation. Nature Reviews Nephrol 11:656\u2013666","journal-title":"Nature Reviews Nephrol"},{"issue":"8","key":"4470_CR5","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1016\/j.transproceed.2022.07.012","volume":"54","author":"TB Bugge","year":"2022","unstructured":"Bugge TB, Perch M, Rezahosseini O, Crone CG, Jensen K, Schultz HH et al (2022) Post-transplantation anemia and risk of death following lung transplantation. Transplant Proc 54(8):2329\u20132336","journal-title":"Transplant Proc"},{"issue":"6","key":"4470_CR6","doi-asserted-by":"publisher","first-page":"739","DOI":"10.2165\/00003495-200969060-00007","volume":"69","author":"KA Lyseng-Williamson","year":"2009","unstructured":"Lyseng-Williamson KA, Keating GM (2009) Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 69(6):739\u2013756","journal-title":"Drugs"},{"issue":"11","key":"4470_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113587","volume":"9","author":"G Rosano","year":"2020","unstructured":"Rosano G, Schiefke I, G\u00f6hring U-M, Fabien V, Bonassi S, Stein J (2020) A pooled analysis of serum phosphate measurements and potential hypophosphataemia events in 45 interventional trials with ferric carboxymaltose. J Clin Med 9(11):3587","journal-title":"J Clin Med"},{"issue":"5","key":"4470_CR8","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1111\/bcp.14643","volume":"87","author":"B Schaefer","year":"2021","unstructured":"Schaefer B, Tobiasch M, Viveiros A, Tilg H, Kennedy NA, Wolf M et al (2021) Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside\u2014a systematic review and meta-analysis. Br J Clin Pharmacol 87(5):2256\u20132273","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"4470_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11154-024-09926-5","volume":"26","author":"M Strubbe","year":"2025","unstructured":"Strubbe M, David K, Peene B, Eeckhout B, Van der Schueren B, Decallonne B et al (2025) No longer to be ignored: hypophosphatemia following intravenous iron administration. Rev Endocr Metab Disord 26(1):125\u2013135","journal-title":"Rev Endocr Metab Disord"},{"issue":"5","key":"4470_CR10","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2019.22450","volume":"323","author":"M Wolf","year":"2020","unstructured":"Wolf M, Rubin J, Achebe M, Econs MJ, Peacock M, Imel EA et al (2020) Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. JAMA 323(5):432\u2013443","journal-title":"JAMA"},{"issue":"10270","key":"4470_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0140-6736(20)32594-0","volume":"397","author":"SR Pasricha","year":"2021","unstructured":"Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW (2021) Iron deficiency. Lancet 397(10270):233\u2013248","journal-title":"Lancet"},{"issue":"12","key":"4470_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167146","volume":"11","author":"B Schaefer","year":"2016","unstructured":"Schaefer B, Wurtinger P, Finkenstedt A, Braithwaite V, Viveiros A, Effenberger M et al (2016) Choice of high-dose intravenous iron preparation determines hypophosphatemia risk. PLoS ONE 11(12):e0167146","journal-title":"PLoS ONE"},{"issue":"7","key":"4470_CR13","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1210\/jc.2008-2396","volume":"94","author":"BJ Schouten","year":"2009","unstructured":"Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG (2009) FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab 94(7):2332\u20132337","journal-title":"J Clin Endocrinol Metab"},{"key":"4470_CR14","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/468675","volume":"2015","author":"S Hardy","year":"2015","unstructured":"Hardy S, Vandemergel X (2015) Intravenous iron administration and hypophosphatemia in clinical practice. Int J Rheumatol 2015:468675","journal-title":"Int J Rheumatol"},{"issue":"2","key":"4470_CR15","first-page":"65","volume":"75","author":"V Sari","year":"2017","unstructured":"Sari V, Atiqi R, Hoorn EJ, Heijboer AC, van Gelder T, Hesselink DA (2017) Ferric carboxymaltose-induced hypophosphataemia after kidney transplantation. Neth J Med 75(2):65\u201373","journal-title":"Neth J Med"},{"issue":"4","key":"4470_CR16","doi-asserted-by":"publisher","first-page":"S220","DOI":"10.1016\/j.healun.2022.01.1691","volume":"41","author":"L Santulario-Verd\u00fa","year":"2022","unstructured":"Santulario-Verd\u00fa L, Echeverry-Navarrete E, D\u00edez-L\u00f3pez C, Canedo-Castelo M, Juvany-Roig R, Garc\u00eda-Romero E et al (2022) Hypophosphatemia after intravenous ferric carboxymaltose in heart transplant patients. J Heart Lung Transplant 41(4):S220\u2013S221","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"4470_CR17","doi-asserted-by":"publisher","first-page":"F499","DOI":"10.1152\/ajprenal.90489.2008","volume":"297","author":"N Mohebbi","year":"2009","unstructured":"Mohebbi N, Mihailova M, Wagner CA (2009) The calcineurin inhibitor FK506 (tacrolimus) is associated with transient metabolic acidosis and altered expression of renal acid-base transport proteins. Am J Physiol Renal Physiol 297(2):F499-509","journal-title":"Am J Physiol Renal Physiol"},{"issue":"5","key":"4470_CR18","first-page":"205","volume":"2","author":"KC Fragkos","year":"2020","unstructured":"Fragkos KC, Sehgal V, Rogers J, Arulrajan S, Pavanerathan P, Barragry J et al (2020) Hypophosphataemia after intravenous iron therapy with ferric carboxymaltose\u2014real world experience from a tertiary centre in the UK. Gastroenterol Hepatol 2(5):205\u2013214","journal-title":"Gastroenterol Hepatol"},{"issue":"12","key":"4470_CR19","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1097\/01.ASN.0000144207.44469.BE","volume":"15","author":"Y Moz","year":"2004","unstructured":"Moz Y, Levi R, Lavi-Moshayoff V, Cox KB, Molkentin JD, Silver J et al (2004) Calcineurin Abeta is central to the expression of the renal type II Na\/Pi co-transporter gene and to the regulation of renal phosphate transport. J Am Soc Nephrol 15(12):2972\u20132980","journal-title":"J Am Soc Nephrol"},{"key":"4470_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2025.107265","volume":"214","author":"JA Dominguez Rieg","year":"2025","unstructured":"Dominguez Rieg JA, Domenech Acevedo M, Nogueira Coelho J, Stevens M, Thomas L, Rieg T (2025) Distinct roles of ferric carboxymaltose and ferric derisomaltose on phosphate homeostasis in iron deficiency anemia. Eur J Pharm Sci 214:107265","journal-title":"Eur J Pharm Sci"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04470-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-026-04470-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04470-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:57:03Z","timestamp":1784912223000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-026-04470-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":20,"alternative-id":["4470"],"URL":"https:\/\/doi.org\/10.1007\/s11739-026-04470-3","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare thet they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent to participate in the study. All procedures were reviewed and approved by the Cantonal Ethics Committee Zurich (BASEC-Nr 2022-02302) and conformed to the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}